Upon its preliminary review, FDA determined that the NDA, submitted on June 26, 2017, was not sufficiently complete to permit a substantive review. FDA specified two reasons for the RTF: first, the date wh...查看全文
薛定锷之猫2017-08-30 02:11
$阿索尔达治疗(ACOR)$ 这管理层得上黑名单啊:
2017.03 ampyra专利输掉;Parkinson's Candidate CVT-301 数据不理想;
2017.08 FDA拒绝INBRIJA™ (CVT-301, levodopa inhalation powder) 的NDA查看全文
交易者的天空2017-04-01 03:59
$AKARI THERAPEUTICS PLC(AKTX)$ $小金矿3X空-Direxion(JDST)$ $阿索尔达治疗(ACOR)$ BOFI BBRY
“蒙” 在高点
这个也是“蒙”在高点,add was bad, 最后自己把自己晃出去了。
bounce play scalp
11:30 左右,breaking news, 简单来说就是court rule patent 违规,第一波没赶上,...查看全文
薛定锷之猫2017-02-11 01:46
$阿索尔达治疗(ACOR)$ Feb14号盘前Q4ER;CVT-301治帕金森3期效果好;FDA已批3个药,销售主要靠AMPYRA® (dalfampridine) 缓释片;跟仿制药在打官司。查看全文
$阿索尔达治疗(ACOR)$ 8-K Current report, items 3.01 and 9.01 Accession Number: 0000950170-24-041350 Act: 34 Size: 183 KB 网页链接
$阿索尔达治疗(ACOR)$ 8-K Current report, items 1.01, 1.03, 2.03, 2.04, 7.01, and 9.01 Accession Number: 0000950170-24-039674 Act: 34 Size: 235 KB 网页链接
$阿索尔达治疗(ACOR)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-039464 Act: 34 Size: 18 MB 网页链接
$阿索尔达治疗(ACOR)$ 8-K Current report, items 5.03 and 9.01 Accession Number: 0000950170-24-030816 Act: 34 Size: 303 KB 网页链接
$阿索尔达治疗(ACOR)$ 8-K Current report, items 1.02 and 9.01 Accession Number: 0000950170-24-003763 Act: 34 Size: 192 KB 网页链接
$阿索尔达治疗(ACOR)$ 8-K Current report, item 8.01 Accession Number: 0000950170-23-067363 Act: 34 Size: 149 KB 网页链接
$阿索尔达治疗(ACOR)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-23-063274 Act: 34 Size: 9 MB 网页链接
$阿索尔达治疗(ACOR)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-23-062975 Act: 34 Size: 542 KB 网页链接
$阿索尔达治疗(ACOR)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-23-039975 Act: 34 Size: 9 MB 网页链接
$阿索尔达治疗(ACOR)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-23-039816 Act: 34 Size: 709 KB 网页链接